Neoadjuvant Cemiplimab for CSCC
1-Yr Follow-up of Phase II Study of Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma

Released: October 25, 2023

Activity

Progress
1
Course Completed